Literature DB >> 21707712

Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.

Kristi Baker1, Jonathan Lachapelle, Inti Zlobec, Tarek A Bismar, Luigi Terracciano, William D Foulkes.   

Abstract

AIMS: Results of previous studies on the influence of tumour infiltrating lymphocytes on prognosis of women with breast cancer have been mixed. This study re-evaluates the role of tumour-infiltrating lymphocytes as a prognostic marker in women with breast cancer. METHODS AND
RESULTS: Immunochemistry staining of CD8(+) T cells was performed on a tissue microarray of 1953 breast carcinomas. When all tumours were considered, no association between the lymphocyte count and patient survival was found. In univariate analysis, there was a reduced disease-specific survival for women with oestrogen receptor (ER)-positive tumours with high intraepithelial lymphocyte count (P=0.004). In those with ER-negative tumours, the disease-specific survival was improved when the intraepithelial, stromal and total lymphocyte counts were high, the total lymphocyte count also being an independent prognostic marker on multivariate analysis (P=0.031). When stratified by histological grade, on univariate analysis, the previously observed inferior outcome in women with high lymphocyte count and ER-positive tumours remained significant only if tumours were also of low grade, and the superior outcome in those with ER-negative tumours remained significant if tumours were also of high grade.
CONCLUSIONS: Our results raise the possibility of different immune-tumour interactions based on ER status and histological grade.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707712     DOI: 10.1111/j.1365-2559.2011.03846.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  51 in total

1.  Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.

Authors:  Ekram Gad; Lauren Rastetter; Meredith Slota; Marlese Koehnlein; Piper M Treuting; Yushe Dang; Sasha Stanton; Mary L Disis
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

2.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

3.  CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?

Authors:  Sahar Mahmoud; Andrew Lee; Ian Ellis; Andrew Green
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

4.  Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.

Authors:  Khalid Al-Saleh; Nashwa Abd El-Aziz; Arwa Ali; Waleed Abozeed; Ahmed Abd El-Warith; Ahmed Ibraheem; Jawaher Ansari; Ammar Al-Rikabi; Sufia Husain; Jean-Marc Nabholtz
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

5.  CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer.

Authors:  Gong-Ling Peng; Liang Li; Ya-Wen Guo; Pan Yu; Xing-Jie Yin; Shan Wang; Chun-Ping Liu
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

6.  Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.

Authors:  Hulya Sahin Ozkan; Mustafa Umit Ugurlu; Perran Fulden Yumuk; Handan Kaya
Journal:  Pathol Oncol Res       Date:  2020-07-17       Impact factor: 3.201

Review 7.  The immune response in cancer: from immunology to pathology to immunotherapy.

Authors:  Nicolas A Giraldo; Etienne Becht; Yann Vano; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2015-06-16       Impact factor: 4.064

Review 8.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

9.  Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Shuzhen Liu; Bingshu Chen; Samantha Burugu; Samuel Leung; Dongxia Gao; Shakeel Virk; Zuzana Kos; Wendy R Parulekar; Lois Shepherd; Karen A Gelmon; Torsten O Nielsen
Journal:  JAMA Oncol       Date:  2017-11-09       Impact factor: 31.777

10.  A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Authors:  Masanori Oshi; Fernando A Angarita; Yoshihisa Tokumaru; Li Yan; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-05-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.